{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:52:15Z","timestamp":1781941935589,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016255","name":"INOVIO Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel approaches for malaria prophylaxis remain important. Synthetic DNA-encoded monoclonal antibodies (DMAbs) are a promising approach to generate rapid, direct in vivo host-generated mAbs with potential benefits in production simplicity and distribution coupled with genetic engineering. Here, we explore this approach in a malaria challenge model. We engineered germline-reverted DMAbs based on human mAb clones CIS43, 317, and L9 which target a junctional epitope, major repeat, and minor repeat of the <jats:italic>Plasmodium falciparum<\/jats:italic> circumsporozoite protein (CSP) respectively. DMAb variants were encoded into a plasmid vector backbone and their expression and binding profiles were characterized. We demonstrate long-term serological expression of DMAb constructs resulting in in vivo efficacy of CIS43 GL and 317 GL in a rigorous mosquito bite mouse challenge model. Additionally, we engineered an Fc modified variant of CIS43 and L9-based DMAbs to ablate binding to C1q to test the impact of complement-dependent Fc function on challenge outcomes. Complement knockout variant DMAbs demonstrated similar protection to that of WT Fc DMAbs supporting the notion that direct binding to the parasite is sufficient for the protection observed. Further investigation of DMAbs for malaria prophylaxis appears of importance.<\/jats:p>","DOI":"10.1038\/s41598-022-18375-6","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T14:04:27Z","timestamp":1661177067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model"],"prefix":"10.1038","volume":"12","author":[{"given":"Nicholas J.","family":"Tursi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia M.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevel","family":"Flores-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou A.","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamika","family":"Mathis-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Salgado-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Esquivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline D.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Humeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidel","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"18375_CR1","unstructured":"WHO. World Malaria Report 2021 (World Health Organization, 2021)."},{"issue":"7030","key":"18375_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature03342","volume":"434","author":"RW Snow","year":"2005","unstructured":"Snow, R. W., Guerra, C. A., Noor, A. M., Myint, H. Y. & Hay, S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030), 214\u2013217 (2005).","journal-title":"Nature"},{"issue":"1","key":"18375_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025569","volume":"8","author":"DA Milner Jr","year":"2018","unstructured":"Milner, D. A. Jr. Malaria pathogenesis. Cold Spring Harb. Perspect. Med. 8(1), a025569 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9","key":"18375_CR4","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1080\/21645515.2017.1295906","volume":"13","author":"S Mahmoudi","year":"2017","unstructured":"Mahmoudi, S. & Keshavarz, H. Efficacy of phase 3 trial of RTS, S\/AS01 malaria vaccine: The need for an alternative development plan. Hum. Vaccin. Immunother. 13(9), 2098\u20132101 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"issue":"6906","key":"18375_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nature01107","volume":"419","author":"L Florens","year":"2002","unstructured":"Florens, L. et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 419(6906), 520\u2013526 (2002).","journal-title":"Nature"},{"issue":"6614","key":"18375_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/385336a0","volume":"385","author":"R M\u00e9nard","year":"1997","unstructured":"M\u00e9nard, R. et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 385(6614), 336\u2013340 (1997).","journal-title":"Nature"},{"issue":"2","key":"18375_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032524","volume":"7","author":"C Aldrich","year":"2012","unstructured":"Aldrich, C. et al. Roles of the amino terminal region and repeat region of the Plasmodium berghei circumsporozoite protein in parasite infectivity. PLoS\u00a0One 7(2), e32524 (2012).","journal-title":"PLoS\u00a0One"},{"issue":"4706","key":"18375_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala, F. et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228(4706), 1436\u20131440 (1985).","journal-title":"Science"},{"issue":"2","key":"18375_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","volume":"336","author":"JA Stoute","year":"1997","unstructured":"Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336(2), 86\u201391 (1997).","journal-title":"N. Engl. J. Med."},{"key":"18375_CR10","doi-asserted-by":"crossref","unstructured":"RTS S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet. 386(9988), 31\u201345 (2015).","DOI":"10.1016\/S0140-6736(15)60721-8"},{"issue":"1","key":"18375_CR11","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1172\/JCI156588","volume":"132","author":"F Zavala","year":"2022","unstructured":"Zavala, F. RTS, S: The first malaria vaccine. J. Clin. Investig. 132(1), 4880\u20134894 (2022).","journal-title":"J. Clin. Investig."},{"issue":"10287","key":"18375_CR12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: A randomised controlled trial. Lancet 397(10287), 1809\u20131818 (2021).","journal-title":"Lancet"},{"issue":"10287","key":"18375_CR13","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/S0140-6736(21)01065-5","volume":"397","author":"V Moorthy","year":"2021","unstructured":"Moorthy, V. & Binka, F. R21\/Matrix-M: A second malaria vaccine?. Lancet 397(10287), 1782\u20131783 (2021).","journal-title":"Lancet"},{"issue":"1","key":"18375_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman, S. L. et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6(1), 97\u2013106 (2010).","journal-title":"Hum. Vaccin."},{"issue":"6152","key":"18375_CR15","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341(6152), 1359\u20131365 (2013).","journal-title":"Science"},{"issue":"9","key":"18375_CR16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","volume":"27","author":"M Oneko","year":"2021","unstructured":"Oneko, M. et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: A double-blind, randomized, placebo-controlled phase 2 trial. Nat. Med. 27(9), 1636\u20131645 (2021).","journal-title":"Nat. Med."},{"issue":"1","key":"18375_CR17","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat. Commun. 12(1), 2518 (2021).","journal-title":"Nat. Commun."},{"issue":"5","key":"18375_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko, M. S. et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: A randomised, double-blind phase 1 trial. Lancet Infect. Dis 17(5), 498\u2013509 (2017).","journal-title":"Lancet Infect. Dis"},{"issue":"544","key":"18375_CR19","doi-asserted-by":"publisher","first-page":"eaaz5629","DOI":"10.1126\/scitranslmed.aaz5629","volume":"12","author":"M Roestenberg","year":"2020","unstructured":"Roestenberg, M. et al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med. 12(544), eaaz5629 (2020).","journal-title":"Sci. Transl. Med."},{"key":"18375_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3389\/fimmu.2019.01227","volume":"10","author":"YS Goh","year":"2019","unstructured":"Goh, Y. S., McGuire, D. & R\u00e9nia, L. Vaccination with sporozoites: Models and correlates of protection. Front. Immunol. 10, 1227 (2019).","journal-title":"Front. Immunol."},{"issue":"4","key":"18375_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24(4), 408\u2013416 (2018).","journal-title":"Nat. Med."},{"issue":"48","key":"18375_CR22","doi-asserted-by":"publisher","first-page":"E10438","DOI":"10.1073\/pnas.1715812114","volume":"114","author":"D Oyen","year":"2017","unstructured":"Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc. Natl. Acad. Sci. 114(48), E10438\u2013E10445 (2017).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"18375_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53(4), 733\u201344.e8 (2020).","journal-title":"Immunity"},{"issue":"3","key":"18375_CR24","doi-asserted-by":"publisher","first-page":"e143958","DOI":"10.1172\/jci.insight.143958","volume":"6","author":"NK Kisalu","year":"2021","unstructured":"Kisalu, N. K. et al. Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. JCI Insight. 6(3), e143958 (2021).","journal-title":"JCI Insight."},{"issue":"9","key":"18375_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","volume":"385","author":"MR Gaudinski","year":"2021","unstructured":"Gaudinski, M. R. et al. A monoclonal antibody for malaria prevention. N. Engl. J. Med. 385(9), 803\u2013814 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"18375_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJMoa2000226","volume":"383","author":"JG Low","year":"2020","unstructured":"Low, J. G. et al. Phase 1 trial of a therapeutic anti-yellow fever virus human antibody. N. Engl. J. Med. 383(5), 452\u2013459 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"18375_CR27","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1016\/j.cell.2021.06.002","volume":"184","author":"R Copin","year":"2021","unstructured":"Copin, R. et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184(15), 3949\u201361.e11 (2021).","journal-title":"Cell"},{"issue":"7821","key":"18375_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584(7821), 443\u2013449 (2020).","journal-title":"Nature"},{"key":"18375_CR29","doi-asserted-by":"crossref","unstructured":"Loo, Y.-M., McTamney, P. M., Arends, R. H., Gasser, R. A., Abram, M. E., Aksyuk, A. et al. AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans. medRxiv. 2021:2021.08.30.21262666.","DOI":"10.1101\/2021.08.30.21262666"},{"issue":"3","key":"18375_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","volume":"34","author":"A Patel","year":"2020","unstructured":"Patel, A., Bah, M. A. & Weiner, D. B. In vivo delivery of nucleic acid-encoded monoclonal antibodies. BioDrugs 34(3), 273\u2013293 (2020).","journal-title":"BioDrugs"},{"issue":"5","key":"18375_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","volume":"1","author":"B Kelley","year":"2009","unstructured":"Kelley, B. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. MAbs 1(5), 443\u2013452 (2009).","journal-title":"MAbs"},{"issue":"1","key":"18375_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41467-017-00576-7","volume":"8","author":"A Patel","year":"2017","unstructured":"Patel, A. et al. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nat. Commun. 8(1), 637 (2017).","journal-title":"Nat. Commun."},{"issue":"7","key":"18375_CR33","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.celrep.2018.10.062","volume":"25","author":"A Patel","year":"2018","unstructured":"Patel, A. et al. In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model. Cell Rep. 25(7), 1982\u201393.e4 (2018).","journal-title":"Cell Rep."},{"issue":"1","key":"18375_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41541-017-0020-x","volume":"2","author":"STC Elliott","year":"2017","unstructured":"Elliott, S. T. C. et al. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections. NPJ Vaccines. 2(1), 18 (2017).","journal-title":"NPJ Vaccines."},{"issue":"2","key":"18375_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1172\/JCI132779","volume":"130","author":"MC Wise","year":"2020","unstructured":"Wise, M. C. et al. In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J. Clin. Investig. 130(2), 827\u2013837 (2020).","journal-title":"J. Clin. Investig."},{"key":"18375_CR36","doi-asserted-by":"publisher","first-page":"12616","DOI":"10.1038\/srep12616","volume":"5","author":"S Flingai","year":"2015","unstructured":"Flingai, S. et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis\/immunotherapy. Sci. Rep. 5, 12616 (2015).","journal-title":"Sci. Rep."},{"issue":"3","key":"18375_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/infdis\/jiw111","volume":"214","author":"K Muthumani","year":"2016","unstructured":"Muthumani, K. et al. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya virus. J. Infect. Dis. 214(3), 369\u2013378 (2016).","journal-title":"J. Infect. Dis."},{"issue":"22","key":"18375_CR38","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1158\/0008-5472.CAN-18-1429","volume":"78","author":"EK Duperret","year":"2018","unstructured":"Duperret, E. K. et al. Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo. Cancer Res. 78(22), 6363\u20136370 (2018).","journal-title":"Cancer Res."},{"issue":"2","key":"18375_CR39","doi-asserted-by":"publisher","first-page":"e00242","DOI":"10.1128\/mBio.00242-21","volume":"12","author":"EM Parzych","year":"2021","unstructured":"Parzych, E. M. et al. Synthetic DNA delivery of an optimized and engineered monoclonal antibody provides rapid and prolonged protection against experimental gonococcal infection. MBio 12(2), e00242-e321 (2021).","journal-title":"MBio"},{"issue":"6176","key":"18375_CR40","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343(6176), 1260\u20131263 (2014).","journal-title":"Science"},{"issue":"1","key":"18375_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12916-018-1054-2","volume":"16","author":"L Kurtovic","year":"2018","unstructured":"Kurtovic, L. et al. Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. BMC Med. 16(1), 61 (2018).","journal-title":"BMC Med."},{"issue":"1","key":"18375_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-019-1277-x","volume":"17","author":"L Kurtovic","year":"2019","unstructured":"Kurtovic, L. et al. Induction and decay of functional complement-fixing antibodies by the RTS, S malaria vaccine in children, and a negative impact of malaria exposure. BMC Med. 17(1), 45 (2019).","journal-title":"BMC Med."},{"issue":"7","key":"18375_CR43","doi-asserted-by":"publisher","first-page":"e00920","DOI":"10.1128\/IAI.00920-17","volume":"86","author":"MC Behet","year":"2018","unstructured":"Behet, M. C. et al. The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites. Infect. Immun. 86(7), e00920-e1017 (2018).","journal-title":"Infect. Immun."},{"issue":"suppl_1","key":"18375_CR44","doi-asserted-by":"publisher","first-page":"D301","DOI":"10.1093\/nar\/gkp946","volume":"38","author":"F Ehrenmann","year":"2009","unstructured":"Ehrenmann, F., Kaas, Q. & Lefranc, M.-P. IMGT\/3Dstructure-DB and IMGT\/DomainGapAlign: A database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. Nucleic Acids Res. 38(suppl_1), D301\u2013D307 (2009).","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"18375_CR45","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1101\/pdb.prot5636","volume":"2011","author":"F Ehrenmann","year":"2011","unstructured":"Ehrenmann, F. & Lefranc, M.-P. IMGT\/DomainGapAlign: IMGT standardized analysis of amino acid sequences of variable, constant, and groove domains (IG, TR, MH, IgSF, MhSF). Cold Spring Harb. Protoc. 2011(6), 5636 (2011).","journal-title":"Cold Spring Harb. Protoc."},{"issue":"4","key":"18375_CR46","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000019115","volume":"16","author":"D Scaviner","year":"1999","unstructured":"Scaviner, D., Barbi\u00e9, V., Ruiz, M. & Lefranc, M. P. Protein displays of the human immunoglobulin heavy, kappa and lambda variable and joining regions. Exp. Clin. Immunogenet. 16(4), 234\u2013240 (1999).","journal-title":"Exp. Clin. Immunogenet."},{"issue":"10","key":"18375_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00728-20","volume":"89","author":"SM Reeder","year":"2021","unstructured":"Reeder, S. M. et al. Strategic variants of CSP delivered as SynDNA vaccines demonstrate heterogeneity of immunogenicity and protection from Plasmodium infection in a murine model. Infect. Immun. 89(10), e0072820 (2021).","journal-title":"Infect. Immun."},{"issue":"1","key":"18375_CR48","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12936-019-3055-9","volume":"18","author":"Y Flores-Garcia","year":"2019","unstructured":"Flores-Garcia, Y. et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18(1), 426 (2019).","journal-title":"Malar. J."},{"issue":"24","key":"18375_CR49","doi-asserted-by":"publisher","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","volume":"75","author":"M Hezareh","year":"2001","unstructured":"Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. & Parren, P. W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75(24), 12161\u201312168 (2001).","journal-title":"J. Virol."},{"issue":"1","key":"18375_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns, P. & J\u00f6nsson, F. Mouse and human FcR effector functions. Immunol. Rev. 268(1), 25\u201351 (2015).","journal-title":"Immunol. Rev."},{"issue":"6","key":"18375_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000323","volume":"17","author":"S Gulati","year":"2019","unstructured":"Gulati, S. et al. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 17(6), e3000323 (2019).","journal-title":"PLoS Biol."},{"issue":"4","key":"18375_CR52","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","volume":"166","author":"EE Idusogie","year":"2001","unstructured":"Idusogie, E. E. et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166(4), 2571\u20132575 (2001).","journal-title":"J. Immunol."},{"issue":"1","key":"18375_CR53","doi-asserted-by":"publisher","first-page":"15001","DOI":"10.1038\/sigtrans.2015.1","volume":"1","author":"S Bogdanovich","year":"2016","unstructured":"Bogdanovich, S. et al. Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduct. Target. Ther. 1(1), 15001 (2016).","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6166","key":"18375_CR54","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/332738a0","volume":"332","author":"AR Duncan","year":"1988","unstructured":"Duncan, A. R. & Winter, G. The binding site for C1q on IgG. Nature 332(6166), 738\u2013740 (1988).","journal-title":"Nature"},{"issue":"8","key":"18375_CR55","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","volume":"164","author":"EE Idusogie","year":"2000","unstructured":"Idusogie, E. E. et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164(8), 4178\u20134184 (2000).","journal-title":"J. Immunol."},{"issue":"4426","key":"18375_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1126\/science.6985745","volume":"207","author":"N Yoshida","year":"1980","unstructured":"Yoshida, N., Nussenzweig, R. S., Potocnjak, P., Nussenzweig, V. & Aikawa, M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207(4426), 71\u201373 (1980).","journal-title":"Science"},{"issue":"1","key":"18375_CR57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1172\/JCI70349","volume":"124","author":"L Foquet","year":"2014","unstructured":"Foquet, L. et al. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J. Clin. Investig. 124(1), 140\u2013144 (2014).","journal-title":"J. Clin. Investig."},{"issue":"1","key":"18375_CR58","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","volume":"10","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS, S\/AS01E malaria vaccine efficacy. Nat. Commun. 10(1), 2174 (2019).","journal-title":"Nat. Commun."},{"key":"18375_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.smim.2018.08.002","volume":"39","author":"MBB McCall","year":"2018","unstructured":"McCall, M. B. B., Kremsner, P. G. & Mordm\u00fcller, B. Correlating efficacy and immunogenicity in malaria vaccine trials. Semin. Immunol. 39, 52\u201364 (2018).","journal-title":"Semin. Immunol."},{"issue":"1","key":"18375_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-immunol-042617-053301","volume":"37","author":"J Tan","year":"2018","unstructured":"Tan, J., Piccoli, L. & Lanzavecchia, A. The antibody response to Plasmodium falciparum: Cues for vaccine design and the discovery of receptor-based antibodies. Annu. Rev. Immunol. 37(1), 225\u2013246 (2018).","journal-title":"Annu. Rev. Immunol."},{"issue":"12","key":"18375_CR61","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41577-019-0209-5","volume":"19","author":"J-P Julien","year":"2019","unstructured":"Julien, J.-P. & Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat. Rev. Immunol. 19(12), 761\u2013775 (2019).","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"18375_CR62","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24(4), 401\u2013407 (2018).","journal-title":"Nat. Med."},{"issue":"11","key":"18375_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010042","volume":"17","author":"Y Flores-Garcia","year":"2021","unstructured":"Flores-Garcia, Y. et al. The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo. PLoS Pathog. 17(11), e1010042 (2021).","journal-title":"PLoS Pathog."},{"issue":"3","key":"18375_CR64","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","unstructured":"The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3), 531\u2013537 (1998).","journal-title":"Pediatrics"},{"issue":"3","key":"18375_CR65","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1086\/322043","volume":"184","author":"M Boeckh","year":"2001","unstructured":"Boeckh, M. et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J. Infect. Dis. 184(3), 350\u2013354 (2001).","journal-title":"J. Infect. Dis."},{"issue":"4","key":"18375_CR66","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jmb.2019.12.029","volume":"432","author":"T Pholcharee","year":"2020","unstructured":"Pholcharee, T. et al. Diverse antibody responses to conserved structural motifs in Plasmodium falciparum circumsporozoite protein. J. Mol. Biol. 432(4), 1048\u20131063 (2020).","journal-title":"J. Mol. Biol."},{"issue":"1","key":"18375_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12936-020-03181-0","volume":"19","author":"R Raghunandan","year":"2020","unstructured":"Raghunandan, R. et al. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein. Malar. J. 19(1), 113 (2020).","journal-title":"Malar. J."},{"issue":"13","key":"18375_CR68","doi-asserted-by":"publisher","first-page":"e137079","DOI":"10.1172\/jci.insight.137079","volume":"5","author":"SC De Rosa","year":"2020","unstructured":"De Rosa, S. C. et al. Robust antibody and cellular responses induced by DNA-only vaccination for HIV. JCI Insight. 5(13), e137079 (2020).","journal-title":"JCI Insight"},{"issue":"10008","key":"18375_CR69","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386(10008), 2078\u20132088 (2015).","journal-title":"Lancet"},{"key":"18375_CR70","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","volume":"31","author":"P Tebas","year":"2021","unstructured":"Tebas, P. et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. eClinicalMedicine. 31, 100689 (2021).","journal-title":"eClinicalMedicine."},{"issue":"12","key":"18375_CR71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708120","volume":"385","author":"P Tebas","year":"2017","unstructured":"Tebas, P. et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine. N. Engl. J. Med. 385(12), e35 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"10332","key":"18375_CR72","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","volume":"399","author":"A Khobragade","year":"2022","unstructured":"Khobragade, A. et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): The interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet 399(10332), 1313\u20131321 (2022).","journal-title":"Lancet"},{"issue":"10","key":"18375_CR73","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrg2432","volume":"9","author":"MA Kutzler","year":"2008","unstructured":"Kutzler, M. A. & Weiner, D. B. DNA vaccines: Ready for prime time?. Nat. Rev. Genet. 9(10), 776\u2013788 (2008).","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"18375_CR74","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4049\/jimmunol.2000429","volume":"205","author":"A McNee","year":"2020","unstructured":"McNee, A. et al. Establishment of a pig influenza challenge model for evaluation of monoclonal antibody delivery platforms. JImmunol. 205(3), 648\u2013660 (2020).","journal-title":"JImmunol."},{"issue":"1","key":"18375_CR75","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41467-019-08528-z","volume":"10","author":"L Reiling","year":"2019","unstructured":"Reiling, L. et al. Targets of complement-fixing antibodies in protective immunity against malaria in children. Nat. Commun. 10(1), 610 (2019).","journal-title":"Nat. Commun."},{"issue":"3","key":"18375_CR76","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.immuni.2015.02.012","volume":"42","author":"J Boyle Michelle","year":"2015","unstructured":"Boyle Michelle, J. et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 42(3), 580\u2013590 (2015).","journal-title":"Immunity"},{"issue":"6","key":"18375_CR77","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1084\/jem.151.6.1504","volume":"151","author":"P Potocnjak","year":"1980","unstructured":"Potocnjak, P., Yoshida, N., Nussenzweig, R. S. & Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151(6), 1504\u20131513 (1980).","journal-title":"J. Exp. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18375-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:32:08Z","timestamp":1669361528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-18375-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["18375"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-18375-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.M.H is an employee of Inovio Pharmaceuticals and as such receives salary and benefits, including ownership of stock and stock options, from the company. D.B.W. has received grant funding,  speaking honoraria, fees for consulting, and participates in industry collaborations,\u00a0including serving on scientific review committees and board series. Remuneration received by D.B.W. includes direct payments, stock or stock options, and in the interest of disclosure D.B.W. discloses the following paid associations with commercial partners: GeneOne (Consultant), Geneos (Advisory Board), AstraZeneca (Advisory Board, Speaker), Inovio (BOD, SRA, Stock), Sanofi (Advisory Board), BBI (Advisory Board). N.J.T., S.M.R., Y.F-G., M.A.B., S. M-T., B. S-J., R.E., Z.X., J.D.C., A.P., and F.Z. have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14313"}}